Noa Therapeutics raises $2.2 million in pre-seed funding led by UCeed and other investors to develop drugs for inflammatory diseases.

Noa Therapeutics, a Toronto-based pre-clinical biotech startup, has successfully closed a $2.2-million CAD pre-seed round of funding. The round was led by UCeed, with participation from Ontario Centre of Innovation Life Science Innovation Fund, Archangel Network’s StarForge and Phoenix Fire funds, Golden Triangle Angel Network, Angel One Investor Network, and NorthSpring Capital Partners. The funding will be used to advance the lead drug candidate for atopic dermatitis and support the hit-to-lead phase for treating barrier dysfunction-related inflammatory diseases.